Merck (NYSE:MRK) announced on Thursday that its Phase 3 KEYNOTE-B96 trial for its anti-PD-1 therapy Keytruda reached the ...

Merck leads U.S. pharma in 2025, but faces Keytruda patent loss by 2028. Click for my look at MRK stock ahead of its upcoming ...

Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when ...

TRENTON, N.J. — Drugmaker Merck & Co. said Wednesday that it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type ...

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Merck & Co., Inc.

Reversing a previous denial, the U.K.'s cost watchdogs have endorsed Merck’s Keytruda for some patients with advanced lung cancer after weighing new data and a new discount. The move will affect about ...

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express ...

If you have a certain type of cancer, your doctor may suggest Imfinzi (durvalumab) or Keytruda (pembrolizumab) as a treatment option for you. Imfinzi and Keytruda are immunotherapy medications, ...

Merck's (MRK 1.63%) cancer immunology drug, Keytruda, is already one of the best-selling drugs in the world and is well on track to becoming the No. 1 drug by revenue within the next few years. Having ...